Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Today's 3 Worst Stocks in the S&P 500

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

The stock market ended lower today, though the losses weren't anything like the sharp daily declines investors have been getting used to this year. While it may feel like 2014's brought nothing but pain and hardship to your portfolio, the S&P 500 Index (SNPINDEX: ^GSPC  ) is down just 5.1% so far this year. Keep in mind, too, that the stocks entered 2014 at all-time highs, so Wall Street's still doing OK. With little macro news to fuel excitement, the benchmark S&P index fell 3 points, or 0.2%, to end at 1,751.

Of course, in any grouping of 500 stocks, there will be dramatic decliners no matter what the broader market does, and Cerner (NASDAQ: CERN  ) shareholders were the victims of that phenomenon today. Cerner's stock slumped 6%, even though its quarterly results -- which it announced Tuesday afternoon -- were largely in line with expectations. Sales grew at a 12% yearly rate in the fourth quarter, slightly exceeding forecasts. Projected first quarter earnings of $0.36-$0.37 per share were the culprit here, narrowly missing Wall Street's $0.38 EPS estimate. For stocks with high multiples like Cerner, even minor disappointments like this can send shares spiraling downward.

Gilead Sciences (NASDAQ: GILD  ) investors were victims of very similar circumstances today, as shares dropped 4.7% after yesterday's earnings. Gilead Sciences basically had a blowout quarter, beating profit estimates by 10% and revenue expectations by 9.5%. But it was what Gilead didn't address that sent shivers through investors' spines. The company's Hepatitis-C treatment, Sovaldi, has been the subject of much speculation on Wall Street; Sovaldi's potential success could act as a catalyst for the stock if it sells well. Gilead, however, chose not to even project what Sovaldi sales would be like in the coming year stoking fears that expectations for the treatment are too high.

Finally, shares of San Antonio-based petroleum refiner Valero Energy (NYSE: VLO  ) lost 3.9% Wednesday. Sadly there's nothing too dramatic to report about the slump today -- oil and gas stocks were simply the worst performers in the stock market today. On top of that, Valero Energy shares are fairly volatile, and they've rallied more than 25% in the past six months, so investors may merely be cashing in on gains. Trading at a P/E of just 9.3 while paying a 2% annual dividend, Valero still looks like a solid, if low-growth, option for more conservative long-term investors.

2 game-changing biotechs revolutionizing the way we treat cancer
Gilead Sciences may have taken a hit today, but it deserves praise for its efforts in the Hepatitis-C market. The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2825878, ~/Articles/ArticleHandler.aspx, 8/31/2015 11:30:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

John Divine

Fool since 2012, unique fingerprints since birth. Age 7: Put lifetime savings ($18.37!) in the bank, became disillusioned with low interest, and a fascination with the stock market was born.

Today's Market

updated Moments ago Sponsored by:
DOW 16,519.24 -123.77 -0.74%
S&P 500 1,975.86 -13.01 -0.65%
NASD 4,798.44 -29.88 -0.62%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 11:20 AM
^GSPC $1976.00 Down -12.87 -0.65%
S&P 500 INDEX CAPS Rating: No stars
CERN $62.50 Down -0.63 -1.00%
Cerner CAPS Rating: ****
GILD $106.53 Down -1.25 -1.16%
Gilead Sciences CAPS Rating: *****
VLO $59.94 Up +0.94 +1.59%
Valero Energy Corp CAPS Rating: ****